Conversely, T-DXd administered due to the presence of HER2-low showed excellent effectiveness. Performing a re-biopsy is crucial due to the possible loss of estrogen receptors, which would require a change in therapeutic strategy no longer based on endocrine therapy. In cases that remain luminal, knowledge of the mutational profile may help to offer patients novel targeted treatments.

2 days ago

Journal

HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • RB1 (RB Transcriptional Corepressor 1)

HER-2 positive • HR positive • HER-2 negative • RB1 mutation • ESR1 mutation

Enhertu (fam-trastuzumab deruxtecan-nxki) • Verzenio (abemaciclib)

A Phase 1 Study of HDM2017 in Advanced Solid Tumors (clinicaltrials.gov)

P1, N=96, Recruiting, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

2 days ago

New P1 trial

SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)

P2, N=180, Recruiting, AbbVie | Not yet recruiting --> Recruiting | Phase classification: P2/3 --> P2

2 days ago

Enrollment open • Phase classification • Adverse events

Tecentriq (atezolizumab) • carboplatin • etoposide IV • Zepzelca (lurbinectedin) • ABBV-706

A Clinical Study of SHR-A1811(sc) Subcutaneous Injection in Patients With Solid Tumor (clinicaltrials.gov)

P1, N=107, Not yet recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd.

2 days ago

New P1 trial

trastuzumab rezetecan (SHR-A1811)

Liposomal irinotecan in patients with HER2-negative breast cancer and brain metastases: The PHENOMENAL phase 2 study. (PubMed, Eur J Cancer)

nal-IRI demonstrated IC activity in HER2[-] BC with BMs. While overall efficacy was limited and long-term outcomes remain poor, these results highlight the unmet need in this challenging population and support the importance of developing more treatment strategies.

3 days ago

P2 data • Journal

HER-2 (Human epidermal growth factor receptor 2)

HR positive • HER-2 negative

Onivyde (nanoliposomal irinotecan)

Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer. (PubMed, N Engl J Med)

In patients with high-risk, residual invasive HER2-positive breast cancer, postneoadjuvant T-DXd resulted in a significantly higher likelihood of invasive disease-free survival than T-DM1; toxic effects were mainly gastrointestinal and hematologic. An important identified risk of T-DXd is interstitial lung disease, which requires appropriate monitoring and management. (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Breast05 ClinicalTrials.gov number, NCT04622319.).

3 days ago

Journal

HER-2 (Human epidermal growth factor receptor 2)

HER-2 positive • EGFR positive

Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki)

The KIF18A Inhibitor ATX020 Induces Mitotic Arrest and DNA Damage in Chromosomally Instable High-Grade Serous Ovarian Cancer Cells. (PubMed, Cells)

Mechanistically, ATX020 blocks KIF18A's plus-end movement on spindle fibers, increasing spindle length, resulting in chromosomal mis-segregation, aneuploidy, and DNA damage. Our findings suggest that ATX020 inhibits CIN+ HGSOC cells mainly by inducing mitotic arrest and DNA damage, disrupting KIF18A's function crucial for mitosis.

3 days ago

Journal

TP53 (Tumor protein P53) • KIF18A (Kinesin Family Member 18A)

TP53 mutation

Investigating the prognostic potential of PTPN11 gene in papillary thyroid carcinoma: A comprehensive study of bulk and single cell transcriptome. (PubMed, Medicine (Baltimore))

It exhibited strong binding affinities with VX-11e, irinotecan, and dactinomycin. Endothelial cells were identified as key cells; the occurrence of PTC reduced their quantity and affected the frequency/intensity of their interactions with mast cells. In conclusion, PTPN11 holds promise as a prognostic marker for PTC and is of great value for clinical management.

3 days ago

Journal

PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11) • NCAM1 (Neural cell adhesion molecule 1) • DACT2 (Dishevelled Binding Antagonist Of Beta Catenin 2) • MMP8 (Matrix Metallopeptidase 8)

irinotecan • dactinomycin • VTX-11e

Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial (clinicaltrials.gov)

P3, N=129, Not yet recruiting, City of Hope Medical Center

3 days ago

New P3 trial

Avastin (bevacizumab) • irinotecan • Aybintio (bevacizumab biosimilar) • leucovorin calcium • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Jelmyto (mitomycin urothelial gel) • fluorouracil topical

OptiTROP-Breast01: SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer (clinicaltrials.gov)

P3, N=254, Active, not recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Trial completion date: Mar 2025 --> Jun 2027

3 days ago

Trial completion date

HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)

HER-2 negative • HER-2 expression • HER-2 negative + HR positive + BRCA mutation

gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Jiataile (sacituzumab tirumotecan)